We have previously shown that the local-membrane bound 4-1BB ligand and IL-12 gene transfer induced a significant antitumor response in a mouse colon carcinoma model. However, a high viral dose was required in order to achieve the best efficacy. In this study, we hypothesize that the systemic administration of soluble Ig-4-1BB ligand can give rise to better T-cell immune activation than local gene delivery. With potential clinical applications in mind, we further compare whether the natural 4-1BB ligand fused to mouse IgG2a (Ig-4-1BBL) would be as effective as the agonistic anti-4-1BB antibody. The dimeric form of Ig-4-1BBL was purified from HeLa cells transduced with a recombinant adenovirus (ADV/ Ig-4-1BBL) expressing Ig-4-1BBL. Functional activity was confirmed by the ligand's ability to bind to activated splenic T cells or bone marrow (BM)-derived dendritic cells (DCs) that express 4-1BB receptor. The soluble Ig-4-1BBL efficiently costimulated CD3-activated T-cell proliferation in vitro. More importantly, it induced tumor-specific CTLs as effectively as the agonistic anti-4-1BB antibody. When combined with IL-12 gene transfer, systemic administration of the Ig-4-1BBL proved to be more potent than local gene delivery. In addition, the Ig-4-1BBL is as potent as the agonistic anti-4-1BB antibody for the treatment of hepatic MCA26 colon carcinoma, resulting in 50% complete tumor regression and long-term survival. In long-term surviving mice, both treatment modalities induced persistent tumor-specific CTL activity. In summary, these results suggest that the systemic delivery of Ig-4-1BBL can generate a better antitumor response than local gene delivery. Ig-4-1BBL had equivalent biological functions when compared to the agonistic anti-4-1BB antibody. Thus, soluble 4-1BBL dimmer can be developed as a promising agent for cancer therapy in humans. Gene Therapy (2005) 12, 1526-1533.
Introduction
Lymphocytes require two signals for optimal activation: T-cell receptor (TCR) ligation and costimulation. Costimulation provides an independent stimulus that influences the outcome of the interaction between T cells and antigen-presenting cells (APC). Without costimulation, antigen primed T cells will undergo apoptosis or become anergic. 4-1BB (CD137), along with other costimulatory molecules, plays an important role in this complex interplay. 1, 2 4-1BB is an inducible protein expressed on the surface of activated T lymphocytes, 3 natural killer (NK) cells, 4 and dendritic cells (DCs). [5] [6] [7] It is a member of the tumor necrosis factor/nerve growth factor family of receptors that includes CD40, CD27, CD30, and OX-40. Its natural ligand, 4-1BB ligand (4-1BBL), is expressed on activated APC, including B cells, macrophages, and DCs. 8 Ligation of 4-1BB by either its natural ligand, or experimentally by an agonistic antibody induces activation of the NF-kB, c-Jun NH 2 -terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38 signaling pathways. 4-1BB signaling plays a conflicting role to Fas with the ability to rescue activated T cells from activation-induced cell death and leads to long-term survival of CD8T cells in vivo. It is a regulatory activator of the type 1 immune response by promoting T cells to generate IL-2, IFN-g, TNF-a, and predominantly CD8 + T-cell-mediated immune response. 9 In vivo activation of 4-1BB signaling by the administration of agonistic 4-1BB antibodies or 4-1BB L-transduced tumor cells resulted in the regression of some tumors. 6, [9] [10] [11] We previously showed that the combination of 4-1BB costimulation by an agonistic antibody with IL-12 gene transfer induced a significant synergistic antitumor response in a mouse colon carcinoma model. In order to minimize the inherent dangers involved with the introduction of foreign antigen, for example, agonistic antibody, to patients in future clinical trials, we further tested the efficacy of an adenovirus (ADV) expressing membrane-bound 4-1BBL (ADV/4-1BBLm), which is the natural ligand for this receptor. The combination of ADV/4-1BBLm with IL-12 recombinant adenovirus (ADV/IL-12) showed a synergistic therapeutic effect in mouse colon and breast cancer models. 12, 13 However, the maximal tolerable dose of ADV/4-1BBLm together with a high dose of ADV/IL-12 was needed to achieve treatment effect for this low-immunogenic MCA26 colon cancer. A reduction in the virus dose resulted in a diminished therapeutic effect. One likely explanation is that local expression of 4-1BBL on tumor cells after adenovirus transduction was less effective in activating DCs and systemic T-cell responses than systemic antibody therapy, as cancer cells may secrete immunosuppressive factors and cannot present tumor antigens efficiently to naïve T cells. In contrast, antibody, by virtue of systemic distribution, is able to more efficiently interact with proficient immune cells in the lymphoid organs. Therefore, to facilitate the clinical translation of this treatment modality, it is important to test whether systemic administration of soluble 4-1BBL would be superior to local delivery of ADV/4-1BBLm and at least as efficacious as antibody treatment. In this study, we generated a soluble Ig-4-1BBL fusion protein and compared it head-to-head in vitro and in vivo with the potent and well-established agonistic anti-4-1BB antibody.
Results

Construction of Ig-4-1BBL-expressing adenoviral vector
The full-length expression cassette of the Ig-4-1BBL plasmid was sequenced. No mutations were detected in the insert, which consists of the 251 bp preproinsulin/ hIL-2 leader, the 699 bp mouse IgG2a (hinge-CH2-CH3) fragment and the 621 bp extracellular domain of mouse 4-1BBL (Figure 1 ).
Antitumor effect of local immunotherapy with ADV/Ig-4-1BBL and ADV-mIL-12
Mice bearing hepatic colon tumors measuring between 5 Â 5 and 7 Â 7 mm 2 were randomly assigned to one of the five treatment groups (n ¼ 5-8 animals/group). As shown in Figure 2 , all mice in the ADV/IL-12+ADV/ DL312 control group and ADV/Ig-4-1BBL group died within 21-41 days after tumor implantation. In all, 60% (3/5) of the animals treated with ADV/IL-12 in combination with anti-4-1BB antibody survived more than 120 days after tumor inoculation (Po0.05 versus control group), whereas fewer long-term surviving animals were observed in the groups treated with intratumoral injections of ADV/IL-12+ADV/Ig-4-1BBL, 43% (3/7) of those receiving the high viral dose (3.2 Â 10 9 PFU) and 25% (2/8) of those receiving lower viral dose (1.6 Â 10 9 PFU) (P40.05, nonsignificant versus control group). The results indicated that the ADV/Ig-4-1BBL may have some effect and the effect seemed to be dose-dependent. However, it is possible that the soluble Ig-4-1BBL expressed locally in the tumor was not sufficient to optimally activate a systemic immune response capable of providing a survival advantage. Systemic Ig-4-1BB ligand and IL-12 gene therapy for hepatic colon carcinoma D-P Xu et al
Purification and characterization of mouse Ig-4-1BBL protein
Owing to the inferior activity of Ig-4-1BBL gene delivery via recombinant adenovirus compared to agonistic anti-4-1BB antibody administration, we decided to test systemic delivery of purified Ig-4-1BBL protein. Protein G column-purified protein gave a band corresponding to the expected molecular size of Ig-4-1BBL when separated on a 10% SDS-PAGE gel. As shown in Figure 3a , under reducing conditions in the presence of 2-ME, the Ig-4-1BBL band was around 53 kDa (lane 2), while in the absence of 2-ME the band was around 106 kDa (lane 1), representing the dimeric form of the protein. Anti-4-1BB antibody was reduced into heavy and light chains in the presence of 2-ME (lane 4). Western blot analysis for Ig-4-1BBL showed a result in agreement with the SDS-PAGE analysis (Figure 3b) .
FACS analysis was used to study the binding of Ig-4-1BBL and anti-4-1BB antibody to the 4-1BB receptor on the cell surface. Both Ig-4-1BBL and anti-4-1BB antibody bound to activated T cells. In a competitive inhibition assay using a 10-fold higher dose of competitor, anti-4-1BB antibody had no inhibitory effect on FITC-Ig-4-1BBL binding to activated T cells (Figure 4a ), while Ig-4-1BBL only slightly inhibited the binding of FITC-anti-4-1BB antibody (Figure 4b ). These data suggest that Ig-4-1BBL and anti-4-1BB antibody may bind different epitopes of the 4-1BB receptor. In addition, both Ig-4-1BBL and anti-4-1BB antibody were able to bind to bone marrow (BM)-derived DCs (Figure 4c ).
Costimulation of T cells via 4-1BB receptor
Furthermore, we performed [ 3 H]thymidine incorporation assays using CD3 preactivated T cells to compare the effect of Ig-4-1BBL versus anti-4-1BB antibody on T-cell proliferation. As shown in Figure 5 , Ig-4-1BBL and anti-4-1BB antibody had an equivalent costimulatory effect in augmenting anti-CD3-initiated T-cell proliferation at the anti-CD3 concentration of 100-333 mg/ml, while rat-Ig showed a 4-9-fold reduced stimulation effect. Systemic Ig-4-1BB ligand and IL-12 gene therapy for hepatic colon carcinoma D-P Xu et al
Induction of CTL activity against tumor cells
The ability of Ig-4-1BBL and anti-4-1BB antibody to induce a tumor-specific CTL response against parental MCA26 targets was examined using splenic effector cells isolated from various treatment groups at day 14 after tumor cell implantation. Animals exhibited a strong CTL response only for short periods of time after Ig-4-1BBL or anti-4-1BB antibody treatment alone ( Figure 6 ). When combined with IL-12 gene transfer, comparable CTL responses were found with both Ig-4-1BBL and anti-4-1BB antibody therapy at all E/T ratios at day 21 after tumor cell implantation. When the group treated with ADV/IL-12 alone was tested at this time point, no significant CTL induction was observed ( Figure 7 ).
Therapeutic effect of Ig-4-1BBL
The antitumor potential of Ig-4-1BBL was evaluated alone or in combination with ADV/IL-12. The effective combination therapy for MCA26 colon carcinoma with ADV/IL-12+anti-4-1BB antibody, as previously established in our laboratory, was used as a positive control. Mice bearing tumors measuring between 5 Â 5 and 7 Â 7 mm 2 were randomly assigned to different groups (n ¼ 7-12 animals/group). As shown in Figure 8 , all mice in the ADV/IL-12+rat Ig-treated group and ADV/ DL312+rat Ig-treated group died around 30 days after tumor implantation. In total, 14% (1/7) of the animals treated with anti-4-1BB antibody alone or Ig-4-1BBL alone survived long-term; 50% (6/12) of the animals treated with Ig-4-1BBL in combination with ADV/IL-12 survived more than 120 days (P ¼ 0.0003 versus IL-12 alone; P ¼ 0.0292 versus Ig-4-1BBL alone). Correspondingly, 50% (6/12) of the animals treated with anti-4-1BB antibody in combination with ADV/IL-12 survived long term (Po0.0001 versus IL-12 alone; P ¼ 0.0076 versus anti-4-1BB antibody alone).
Induction of persistent and systemic antitumor immunity in long-term surviving mice
A persistent antitumor CTL response is a prerequisite for therapeutic success in cancer immunotherapy. We therefore isolated splenocytes from long-term surviving mice and tested for the presence of persistent CTLs. A tumor-specific CTL response developed in all of the Treatment group % lysis of target cells Figure 6 Ig-4-1BBL stimulates CTL response in MCA26 tumor-bearing mice. MCA26 tumor cells were inoculated into the liver of BALB/c mice at day 0. At day 7, the animals bearing 5 Â 5-7 Â 7 mm 2 tumor were selected for treatment. In all, 100 mg of Ig-4-1BB or anti-4-1BB antibody or rat Ig was given i.p. at days 8 and 10. Spleen cells were isolated at day 14 for CTL assay (as described in the text). The CTL activity was blocked by addition of 2 mg of anti-CD3. Each data value represents the mean7s.d. for three samples. 
Discussion
In previous studies, we have shown that the combination of ADV/IL-12 and an agonistic anti-4-1BB antibody was an effective therapy against MCA26 colon cancer in mice.
14 Anti-4-1BB antibody alone or in combination with other agents has also been proven to be effective in some other animal models of cancer.
6,9,10 Therefore, anti-4-1BB antibody may be a potent agent for human cancer therapy.
While it may be logical to generate a humanized form of the agonistic antibody to 4-1BB, anti-4-1BB antibody is not the natural ligand for 4-1BB receptor activation. The natural molecule for 4-1BB activation is membrane bound 4-1BB ligand. Furthermore, the generation of a humanized agonistic antibody is not an easy task. Therefore, the development of natural 4-1BBL as a therapeutic agent for cancer warranted exploration and provides the basis of this study.
4-1BB is a glycoprotein that exists as both a 30-kDa monomer and a 55-kDa dimer on the T-cell surface. 15 4-1BB mediates signaling either by ligation with natural ligand expressed on activated APC or experimentally by binding an anti-4-1BB agonistic antibody. We previously developed a recombinant adenovirus expressing membrane-bound mouse 4-1BBL (ADV/4-1BBLm) consisting of the extracellular domain and the transmembrane domain of 4-1BBL. We used this virus combined with ADV/IL-12 for local gene delivery in tumor tissue and induced a significant antitumor immune response in the low-immunogenic MCA26 tumor model. 12 However, the maximal tolerable dose of ADV/4-1BBLm together with a high dose of ADV/IL-12 was needed to achieve an antitumor effect. We found that the utilization of ADV/4-1BBLm alone failed to induce a significant systemic CTL response against tumor cells in contrast to that seen with the agonistic anti-4-1BB antibody. One possible explanation for this phenomenon could be that intratumoral delivery of ADV/4-1BBL transduced mostly tumor cells, which are known to be poor APCs, and that restricting 2 were randomly assigned to the following groups: &, ADV/IL-12 (7 Â 10 7 PFU)+Ig-4-1BBL, n ¼ 12; B, ADV/IL-12 (7 Â 10 7 PFU)+anti-4-1BB antibody, n ¼ 12; J, ADV/IL-12 (7 Â 10 7 PFU)+rat Ig, n ¼ 9; n, ADV/DL312 (7 Â 10 7 PFU)+rat Ig, n ¼ 9; ,, anti-4-1BB antibody, n ¼ 7; Â , Ig-4-1BBL, n ¼ 7. ADV/IL-12 and ADV/DL312 were injected intratumorally. Anti-4-1BB antibody or Ig-4-1BBL (100 mg/mouse) was given i.p. at days 8 and 10. The survival advantage for the ADV/IL-12+Ig-4-1BB-treated animals was statistically significant compared to ADV/IL-12+rat Ig-treated animals (P ¼ 0.0003) or Ig-4-1BBL-treated animals (P ¼ 0.0292). The reported results are the combination of two consecutive sets of experiments. **Po0.01 log-rank test. Systemic Ig-4-1BB ligand and IL-12 gene therapy for hepatic colon carcinoma D-P Xu et al gene expression to the tumor mass reduced the likelihood that 4-1BBL-expressing tumor cells would be able to prime naïve T cells in secondary lymphoid organs. Based on the above observations, an adenovirus was developed that expresses soluble mouse 4-1BBL fused to the Fc portion of mouse IgG2a (ADV-Ig-4-1BBL). This design allowed monomeric 4-1BBL molecules to form a dimer. The dimer should confer higher binding affinity of Ig-4-1BBL with its receptor. 4-1BB is a member of the TNFR family. Trimerization or multimerization of TNFR/tumor necrosis receptor-associated factors (TRAFs) is required for high-affinity interaction. 16, 17 The study of CD40/CD40L, one of the TNFR/TRAFs members, mAb indicated that bivalent mAb and dimeric or trimeric soluble forms of CD40L exhibit more potent biological activity than monomeric soluble CD40L. 9 PFU/mouse) of ADV/Ig-4-1BBL was used. We also observed obvious toxic reactions such as weakness and tarnished fur when animals were treated with high doses of ADV/Ig-4-1BBL or control ADV/DL312. In addition, ADV/Ig-4-1BBL-treated animals failed to generate systemic CTL two weeks after treatment (data not shown). We speculated that insufficient generation of systemic 4-1BBL protein was the cause of the lower efficacy of this treatment as compared to the anti-4-1BB antibody. Therefore, we would like to produce and purify the Ig-4-1BBL protein in vitro and test the delivery of soluble protein systemically in order to achieve higher concentrations of Ig-4-1BBL in the blood, which should lead to optimal 4-1BB activation.
Ig-4-1BBL protein was obtained by transducing HeLa cells with ADV/Ig-4-1BBL and the protein was purified from the culture supernatant by protein G affinity chromatography. The yield was 1.5-2 mg/l supernatant. The purified protein was shown to be in the dimerized form using SDS-PAGE and Western blot analysis ( Figure  3 ). Both soluble Ig-4-1BBL and anti-4-1BB antibody bound CD3/CD28-activated T cells and BM-derived DCs. Interestingly, Ig-4-1BBL and anti-4-1BB may bind different epitopes of the receptor as evidenced by the lack of competitive inhibition between the two when binding to 4-1BB-expressing cells (Figure 4) . In spite of that, functional analyses showed that the Ig-4-1BBL has equivalent biological function to the anti-4-1BB antibody in costimulating T-cell proliferation, inducing a persistent CTL response and tumor regression. Like anti-4-1BB antibody, Ig-4-1BBL administration also showed a synergism with IL-12 gene transfer in the generation of an antitumor response in vivo. This is consistent with our previous study. 11 When combined with IL-12 gene transfer, 50% of the animals developed a persistent high CTL response resulting in complete tumor regression. Animals that failed to generate a persistent high CTL response eventually succumbed to the tumor. The survival advantage for ADV/IL-12+anti-4-1BB antibody-treated animals was slightly lower in this experiment than in our previous study due to a lower IL-12 dose used and the variation in biological activity between different preparations of the recombinant ADV/IL-12. All long-term surviving animals were able to completely reject a challenge with parental MCA26 cell line, but not with the previously unseen CMS-5 tumor cell line, suggesting that a memory immune mechanism had developed in these animals. It is worth noting that no toxic side effects were observed in any of the animals treated with Ig-4-1BBL.
In summary, we have shown that the dimerized soluble natural ligand for 4-1BB is a potent antitumor agent when given as a systemic treatment, especially when used in combination with IL-12. This study may open the possibility for translation of this powerful immunostimulatory cancer treatment into the clinic, obviating the need to create a humanized agonistic 4-1BB antibody.
Materials and methods
Cell culture
The mouse colon carcinoma cell line, MCA26, was cultured in Dulbecco's modified Eagle's medium (DMEM)/Ham's F12 (1:1 ratio, Cellgro, Herndon, VA, USA) containing 10% fetal calf serum (FBS) (Gibco BRL, Grand Island, NY, USA), 2 mM L-glutamine, 10 mM HEPES buffer, 100 U/ml penicillin, and 100 mg/ml streptomycin (Cellgro). HeLa cells, purchased from American Type Culture Collection (ATCC, Manassas, VA, USA), were maintained in DMEM F12 with the same supplements in the concentrations mentioned above. For culture of lymphocytes, RPMI 1640 medium (Cellgro) containing 10% FBS and antibiotics was supplemented with 50 mM 2-mercaptoethanol.
Vector construction and fusion protein production ADV/IL-12 was generated as previously described. 19 The full-length mouse 4-1BB ligand cDNA was obtained from pLXSHDm4-1BB-ligand (a generous gift from Dr Lieping Chen, Mayo Clinic). The cDNA encoding the extracellular domain of 4-1BB ligand from 104 to 309 amino acids was generated by PCR amplification using specific primer pairs (sense: 5 0 -CCTCTGAAGCTTCGCACCGAGCCT CGGCCAGC-3 0 ; antisense: 5 0 -ATATTGTTGCGGCCGCTC ATTCCCAT-3 0 ) with HindIII and NotI linkers, respectively. The recombinant adenoviral vector expressing 4-1BBL (ADV/4-1BBL) was then constructed by cloning the 4-1BBL fragment into the adenovirus shuttle plasmid pADV/RSV to generate pADV/RSV-4-1BBL. The plasmid was subsequently modified to generate the pADV/RSVIg-4-1BBL by addition of a preproinsulin/human IL-2 leader and a hinge-CH2-CH3 fragment of mouse IgG2a at the 5 0 end of the 4-1BBL. The two pairs of cysteine bonds between the hinge regions for soluble 4-1BB ligand fusion protein provide stability to the dimeric molecule (Figure 1) . The individual fragments of this cassette were amplified using PCR and linked together using overlapping PCR with the following primers: (1) (2) and (3)+ (4) were employed for step 1 and step 2, respectively. For step 3 (overlapping PCR), primers (1)+ (5) were used with the products from step 1 and step 2 as templates. The resulting product was digested with HindIII/Eco47III and cloned into the HindIII/Eco47III-digested pADV/ RSV-4-1BBL plasmid to generate the pADV/RSV-Ig-4-1BBL plasmid. Recombinant ADV was generated by cotransfecting pADV/RSV-Ig-4-1BBL with the adenovirus backbone vector pBHG10 into 293 cells. Viral plaques were collected, and analyzed for correct transgene insertion. The virus was then amplified in 293 cells and purified using double cesium chloride gradient ultracentrifugation. Virus production, purification, and titration were performed by the Vector Core Production Facility, Mount Sinai School of Medicine. For the generation of soluble protein, HeLa cells were infected with this virus at an MOI of 50-100. Following overnight incubation, the cells were washed with PBS and then refed with medium containing 2% very-low-IgG-FBS (Gibco). Following an additional 2-3 days incubation, the conditioned culture supernatant was collected. Cellular debris was removed by centrifugation (1500 r.p.m. Â 10 min) and filtration (0.45 mm), and the supernatant was then loaded onto a protein-G column (Amersham Biosciences Corp., Newark, NJ, USA) for affinity chromatography according to the manufacturer's instructions.
PAGE and Western blot analysis
Purified Ig-4-1BBL protein and anti-4-1BB antibody were mixed with Laemmli sample buffer (BIO-RAD Labs, Hercules, CA, USA) at a 2:1 ratio in the presence or absence of 2-mercaptoethanol (2-ME) and heated at 951C for 5 min before separation on a 10% SDS-PAGE gel. The gel was either stained with Coomassie Blue Stain Solution (BIO-RAD) or transferred to Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Arlington Heights, IL, USA). The membrane was blocked with PBS containing 5% nonfat dried milk, probed with rat anti-mouse 4-1BBL (Pharmingen), followed by HRPdonkey anti-rat IgG (Jackon Immuno Research, West Grove, PA, USA) and visualized with Western blot chemiluminescence reagent (NEN life Science Products, Boston, MA, USA).
Isolation of mononuclear cells (MNCs) from spleen
The spleen cells were prepared by disruption of the organ between two semifrosted microscope slides. Dissociated cells were passed through a 70 mm cell strainer (Becton-Dickinson Labware, Franklin Lakes, NJ, USA), washed in HBSS containing 1% FBS (wash medium), and treated with RBC lysis buffer (Sigma, St Louis, MO, USA). After one more wash, the cell pellet was resuspended in 5 ml of wash medium, underlayed with 5 ml of lymphocyte-M solution (Cellgro), and centrifuged at 1000 g for 20 min at room temperature.
MNCs collected from the interface between lymphocyte-M and the wash medium were isolated and washed again before further analysis.
Splenic T-cell activation and BM cell culture for induction of 4-1BB expression BALB/c splenic T cells were purified using a T-cell enrichment column (R & D, Minneapolis, MN, USA) according to the manufacturer's instructions. The cells were activated with 10 mg/ml of anti-CD3 and 1 mg/ml of anti-CD28 (Southern Biotechnology Inc, Birmingham, AL, USA) for 48 h. For BM cell culture, the femurs and tibia were removed under sterile conditions, both ends of the bones were cut using scissors, and the marrow was flushed out with Hanks balanced salt solution. BM cells (5 Â 10 6 /ml) were cultured in 10% FBS-DMEM containing 200 U/ml of GM-CSF for 11 days with 250 U/ml of TNF-a added for the last 2 days of culture. The cultures were refed with fresh medium containing GM-CSF every 3-4 days. Approximately 50% of the nonadherent cells exhibited a DC phenotype as confirmed by double staining with PE or FITC-conjugated anti-CD11c+anti-I-A/I-E or anti-CD80 antibodies.
Flow cytometry
Anti-4-1BB (2A) and Ig-4-1BBL were conjugated with FITC as previously described. 20 Other FITC or PEconjugated antibodies and the corresponding isotypes were purchased from PharMingen (San Diego, CA, USA). Cells (1 Â 10 6 ) were incubated with Fc-blocking antibody 2.4G2 (ATCC) at 41C for 20-30 min. After washing two times, the cells were incubated with the appropriate FITC or PE-conjugated antibodies and the corresponding isotypes. In some experiments, the unlabeled anti-4-1BB or Ig-4-1BBL was incubated with cells at 41C for 60 min prior to the engagement of FITC-Ig-4-1BBL or FITC-anti-4-1BB. Samples were analyzed for surface phenotype using FACSCalibur and CellQuest software (Becton-Dickinson Labware).
T-cell proliferation
BALB/c splenic T cells were purified using a T-cell enrichment column as mentioned above. T cells (1 Â 10 5 ) were cocultured with 1 Â 10 2 irradiated (2500 rad) splenic cells/well in a 96-well plate. Serial dilutions of anti-CD3 and 10 mg/ml of Ig-4-1BBL, anti-4-1BB, or rat Ig were added to the cultures for 72 h incubation. At 12 h prior to the end of the incubation period, the cells were pulsed with 1 mCi/well of [ 
In vitro cytotoxic assay
The CTL assay required stimulation of splenic cells with irradiated (12 000 rad) parental MCA26 tumor cells (responder: stimulator ¼ 12:1) in the presence of 30 IU/ ml mIL-2 for 5 days. The effectors were incubated with 51 Cr-labeled MCA26 cells for 4 h at 371C at various effector-to-target cell ratios (E/T 100:1 to 12.5:1). The radioactivity released in the supernatant was measured by a gamma counter and cytotoxicity was calculated as follows: (experimental release À spontaneous release)/ (maximal release À spontaneous release) Â 100. ) cells suspended in 10 ml HBSS (Cellgro) were injected into the left lateral lobe. At 7 days after the injection, mice with hepatic tumors measuring between 5 Â 5 and 7 Â 7 mm 2 were randomly allocated into the appropriate treatment and control groups. The hepatic tumor was directly injected with ADV/IL-12, ADV/Ig-4-1BBL, or a control vector ADV/DL312. The recombinant adenoviruses were injected in 50 ml volumes of 10 mM Tris-HCl (pH 7.4) containing 1 mM MgCl 2 /10% (vol/vol) glycerol and Polybrene (20 mg/l) (all from Sigma Chemical Co.). At days 8 and 10, 100 mg of anti-41BB agonistic antibody (clone 2A, isotype, rat-IgG), purified Ig-4-1BBL, or control rat Ig (Accurate Chemical & Scientific Corporation, Westbury, NY, USA) were given i.p. Long-term survival and antitumor response were monitored to assess the treatment outcome. In order to monitor the antitumor response, mice were killed at different time points for the measurement of CTL activity. For tumor cell challenge: 1 Â 10 5 cells/100 ml MCA26 and CMS-5 7 Â 10 5 cells/100 ml were injected subcutaneously into separate flanks of long-term surviving animals. The tumor volume was checked with calipers 3 weeks after cell implantation.
Statistical analysis
Comparisons of survival curves of different groups were made by log-rank test. A P-value o0.05 was considered as statistically significant.
